The roles of inflammation and immune mechanisms in Alzheimer's disease

Alzheimer's and Dementia: Translational Research and Clinical Interventions

Volumn 2, Issue 2, 2016, Pages 99-109

  Van Eldik, Linda J ^a   Carrillo, Maria C ^b   Cole, Patricia E ^c   Feuerbach, Dominik ^d   Greenberg, Barry D ^e   Hendrix, James A ^b   Kennedy, Matthew ^f   Kozauer, Nick ^g   Margolin, Richard A ^h   Molinuevo, José L ^i,j   Mueller, Reinhold ^k   Ransohoff, Richard M ^l   Wilcock, Donna M ^a   Bain, Lisa ^m   Bales, Kelly ⁿ  

^a UNIVERSITY OF KENTUCKY   (United States)

^b ALZHEIMER'S ASSOCIATION   (United States)

^c TAKEDA PHARMACEUTICALS   (United States)

^d NOVARTIS PHARMA AG   (Switzerland)

^e UNIVERSITY HEALTH NETWORK   (Canada)

^f Whitehouse Station Merck   (United States)

^g IQVIA   (United States)

^h CereSpir Inc   (United States)

ⁱ HOSPITAL CLÍNIC   (Spain)

^j Barcelonaßeta Brain Research Center   (Spain)

^k ABBVIE INC   (United States)

^l BIOGEN   (United States)

^m Independent Medical Writer ^*  (United States)

ⁿ PFIZER INC   (United States)

more..

Author keywords

Adaptive immunity; Alzheimer's disease; Astrocyte; Innate immunity; Microglia; Neuroinflammation

Indexed keywords

BENZODIAZEPINE RECEPTOR; NONSTEROID ANTIINFLAMMATORY AGENT;

ADAPTIVE IMMUNITY; ALZHEIMER DISEASE; ASTROCYTE; CELL FUNCTION; CELL POPULATION; DISEASE COURSE; HUMAN; INNATE IMMUNITY; MICROGLIA; NERVE DEGENERATION; NERVOUS SYSTEM INFLAMMATION; NEUROPROTECTION; NONHUMAN; PHAGOCYTOSIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REGULATORY T LYMPHOCYTE; REVIEW; SIGNAL TRANSDUCTION; SYSTEMIC DISEASE;

EID: 84976292860     PISSN: None     EISSN: 23528737     Source Type: Journal    
DOI: 10.1016/j.trci.2016.05.001     Document Type: Review

References (79)

1. A. Alzheimer Über eine eigenartige Erkrankung der Hirnrinde Allgemeine Z Psychiatrie Psychisch Gerichtliche Med 64 1907 146 148
2. M.T. Heneka, M.J. Carson, J. El Khoury, G.E. Landreth, F. Brosseron, D.L. Feinstein, and et al. Neuroinflammation in Alzheimer's disease Lancet Neurol 14 2015 388 405
3. C.A. Szekely, J.E. Thorne, P.P. Zandi, M. Ek, E. Messias, J.C. Breitner, and et al. Nonsteroidal anti-inflammatory drugs for the prevention of Alzheimer's disease: a systematic review Neuroepidemiology 23 2004 159 169
4. C. Colton, and D.M. Wilcock Assessing activation states in microglia CNS Neurol Disord Drug Targets 9 2010 174 191
5. F.L. Heppner, R.M. Ransohoff, and B. Becher Immune attack: the role of inflammation in Alzheimer disease Nat Rev Neurosci 16 2015 358 372
6. D.P. Schafer, and B. Stevens Microglia function in central nervous system development and plasticity Cold Spring Harb Perspect Biol 7 2015 a020545
7. M.G. Tansey, and J.K. Lee Inflammation in nervous system disorders. Introduction Neuroscience 302 2015 1
8. T.R. Jay, C.M. Miller, P.J. Cheng, L.C. Graham, S. Bemiller, M.L. Broihier, and et al. TREM2 deficiency eliminates TREM2+ inflammatory macrophages and ameliorates pathology in Alzheimer's disease mouse models J Exp Med 212 2015 287 295
9. K. Rezai-Zadeh, D. Gate, G. Gowing, and T. Town How to get from here to there: macrophage recruitment in Alzheimer's disease Curr Alzheimer Res 8 2011 156 163
10. V.L. Villemagne, S. Burnham, P. Bourgeat, B. Brown, K.A. Ellis, O. Salvado, and et al. Amyloid beta deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study Lancet Neurol 12 2013 357 367
11. T.L. Sudduth, F.A. Schmitt, P.T. Nelson, and D.M. Wilcock Neuroinflammatory phenotype in early Alzheimer's disease Neurobiol Aging 34 2013 1051 1059
12. T. Jonsson, H. Stefansson, S. Steinberg, I. Jonsdottir, P.V. Jonsson, J. Snaedal, and et al. Variant of TREM2 associated with the risk of Alzheimer's disease N Engl J Med 368 2013 107 116
13. C.M. Lill, A. Rengmark, L. Pihlstrom, I. Fogh, A. Shatunov, P.M. Sleiman, and et al. The role of TREM2 R47H as a risk factor for Alzheimer's disease, frontotemporal lobar degeneration, amyotrophic lateral sclerosis, and Parkinson's disease Alzheimers Dement 11 2015 1407 1416
14. S.E. Hickman, and J. El Khoury TREM2 and the neuroimmunology of Alzheimer's disease Biochem Pharmacol 88 2014 495 498
15. G. Kleinberger, Y. Yamanishi, M. Suarez-Calvet, E. Czirr, E. Lohmann, E. Cuyvers, and et al. TREM2 mutations implicated in neurodegeneration impair cell surface transport and phagocytosis Sci Transl Med 6 2014 243ra86
16. A. Heslegrave, W. Heywood, R. Paterson, N. Magdalinou, J. Svensson, P. Johansson, and et al. Increased cerebrospinal fluid soluble TREM2 concentration in Alzheimer's disease Mol Neurodegener 11 2016 3
17. M. Suarez-Calvet, G. Kleinberger, M.A. Caballero, M. Brendel, A. Rominger, D. Alcolea, and et al. sTREM2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early-stage Alzheimer's disease and associate with neuronal injury markers. EMBO Mol Med 8 2016 466 476
18. A. Griciuc, A. Serrano-Pozo, A.R. Parrado, A.N. Lesinski, C.N. Asselin, K. Mullin, and et al. Alzheimer's disease risk gene CD33 inhibits microglial uptake of amyloid beta Neuron 78 2013 631 643
19. E.M. Bradshaw, L.B. Chibnik, B.T. Keenan, L. Ottoboni, T. Raj, A. Tang, and et al. CD33 Alzheimer's disease locus: altered monocyte function and amyloid biology Nat Neurosci 16 2013 848 850
20. M. Malik, J.F. Simpson, I. Parikh, B.R. Wilfred, D.W. Fardo, P.T. Nelson, and et al. CD33 Alzheimer's risk-altering polymorphism, CD33 expression, and exon 2 splicing J Neurosci 33 2013 13320 13325
21. S. Steinberg, H. Stefansson, T. Jonsson, H. Johannsdottir, A. Ingason, H. Helgason, and et al. Loss-of-function variants in ABCA7 confer risk of Alzheimer's disease Nat Genet 47 2015 445 447
22. M. Malik, J. Chiles 3rd, H.S. Xi, C. Medway, J. Simpson, S. Potluri, and et al. Genetics of CD33 in Alzheimer's disease and acute myeloid leukemia Hum Mol Genet 24 2015 3557 3570
23. S.E. Hickman, N.D. Kingery, T.K. Ohsumi, M.L. Borowsky, L.C. Wang, T.K. Means, and et al. The microglial sensome revealed by direct RNA sequencing Nat Neurosci 16 2013 1896 1905
24. K. Harada, T. Kamiya, and T. Tsuboi Gliotransmitter release from astrocytes: functional, developmental, and pathological implications in the brain Front Neurosci 9 2015 499
25. H.K. Kimelberg, and M. Nedergaard Functions of astrocytes and their potential as therapeutic targets Neurotherapeutics 7 2010 338 353
26. H. Lian, L. Yang, A. Cole, L. Sun, A.C. Chiang, S.W. Fowler, and et al. NFkappaB-activated astroglial release of complement C3 compromises neuronal morphology and function associated with Alzheimer's disease Neuron 85 2015 101 115
27. K.A. Frankola, N.H. Greig, W. Luo, and D. Tweedie Targeting TNF-alpha to elucidate and ameliorate neuroinflammation in neurodegenerative diseases CNS Neurol Disord Drug Targets 10 2011 391 403
28. W.C. Kreisl, C.H. Lyoo, M. McGwier, J. Snow, K.J. Jenko, N. Kimura, and et al. In vivo radioligand binding to translocator protein correlates with severity of Alzheimer's disease Brain 136 2013 2228 2238
29. E. Rodriguez-Vieitez, L. Saint-Aubert, S.F. Carter, O. Almkvist, K. Farid, M. Scholl, and et al. Diverging longitudinal changes in astrocytosis and amyloid PET in autosomal dominant Alzheimer's disease Brain 139 2016 922 936
30. D. Alcolea, E. Vilaplana, J. Pegueroles, V. Montal, P. Sanchez-Juan, A. Gonzalez-Suarez, and et al. Relationship between cortical thickness and cerebrospinal fluid YKL-40 in predementia stages of Alzheimer's disease Neurobiol Aging 36 2015 2018 2023
31. C.L. Sutphen, M.S. Jasielec, A.R. Shah, E.M. Macy, C. Xiong, A.G. Vlassenko, and et al. Longitudinal cerebrospinal fluid biomarker changes in preclinical Alzheimer disease during middle age JAMA Neurol 72 2015 1029 1042
32. J.D. Gispert, G.C. Monte, C. Falcon, A. Tucholka, S. Rojas, R. Sanchez-Valle, and et al. CSF YKL-40 and pTau181 are related to different cerebral morphometric patterns in early AD Neurobiol Aging 38 2016 47 55
33. R. Craig-Schapiro, R.J. Perrin, C.M. Roe, C. Xiong, D. Carter, N.J. Cairns, and et al. YKL-40: a novel prognostic fluid biomarker for preclinical Alzheimer's disease Biol Psychiatry 68 2010 903 912
34. P. Piscopo, R. Rivabene, D. Galimberti, A. Crestini, G. Talarico, N. Vanacore, and et al. Gender effects on plasma PGRN levels in patients with Alzheimer's disease: a preliminary study J Alzheimers Dis 35 2013 313 318
35. H. Zetterberg, D. Wilson, U. Andreasson, L. Minthon, K. Blennow, J. Randall, and et al. Plasma tau levels in Alzheimer's disease Alzheimers Res Ther 5 2013 9
36. W.T. Hu, D.M. Holtzman, A.M. Fagan, L.M. Shaw, R. Perrin, S.E. Arnold, and et al. Plasma multianalyte profiling in mild cognitive impairment and Alzheimer disease Neurology 79 2012 897 905
37. H.M. Snyder, M.C. Carrillo, F. Grodstein, K. Henriksen, A. Jeromin, S. Lovestone, and et al. Developing novel blood-based biomarkers for Alzheimer's disease Alzheimers Dement 10 2014 109 114
38. S.J. Kiddle, M. Sattlecker, P. Proitsi, A. Simmons, E. Westman, C. Bazenet, and et al. Candidate blood proteome markers of Alzheimer's disease onset and progression: a systematic review and replication study J Alzheimers Dis 38 2014 515 531
39. D. Kapogiannis, A. Boxer, J.B. Schwartz, E.L. Abner, A. Biragyn, U. Masharani, and et al. Dysfunctionally phosphorylated type 1 insulin receptor substrate in neural-derived blood exosomes of preclinical Alzheimer's disease FASEB J 29 2015 589 596
40. B. Zhang, C. Gaiteri, L.-G. Bodea, Z. Wang, J. McElwee, A.A. Podtelezhnikov, and et al. Integrated systems approach identifies genetic nodes and networks in late-onset Alzheimer's disease Cell 153 2013 707 720
41. B.A. Kidd, L.A. Peters, E.E. Schadt, and J.T. Dudley Unifying immunology with informatics and multiscale biology Nat Immunol 15 2014 118 127
42. B.A. Kidd, A. Wroblewska, M.R. Boland, J. Agudo, M. Merad, N.P. Tatonetti, and et al. Mapping the effects of drugs on the immune system Nat Biotechnol 34 2016 47 56
43. R.M. Cohen, K. Rezai-Zadeh, T.M. Weitz, A. Rentsendorj, D. Gate, I. Spivak, and et al. A transgenic Alzheimer rat with plaques, tau pathology, behavioral impairment, oligomeric Aβ and frank neuronal loss J Neurosci 33 2013 6245 6256
44. D. Puzzo, W. Gulisano, A. Palmeri, and O. Arancio Rodent models for Alzheimer's disease drug discovery Expert Opin Drug Discov 10 2015 703 711
45. S.J. Webster, A.D. Bachstetter, P.T. Nelson, F.A. Schmitt, and L.J. Van Eldik Using mice to model Alzheimer's dementia: an overview of the clinical disease and the preclinical behavioral changes in 10 mouse models Front Genet 5 2014 88
46. M.E. Tremblay, R.L. Lowery, and A.K. Majewska Microglial interactions with synapses are modulated by visual experience PLoS Biol 8 2010 e1000527
47. M. Prinz, and J. Priller Microglia and brain macrophages in the molecular age: from origina to neuropsychiatric disease Nat Rev Neurosci 15 2014 300 312
48. P.D. Hsu, E.S. Lander, and F. Zhang Development and applications of CRISPR-Cas9 for genome engineering Cell 157 2014 1262 1278
49. J. Vom Berg, S. Prokop, K.R. Miller, J. Obst, R.E. Kalin, I. Lopategui-Cabezas, and et al. Inhibition of IL-12/IL-23 signaling reduces Alzheimer's disease-like pathology and cognitive decline Nat Med 18 2012 1812 1819
50. C.J. Barnum, X. Chen, J. Chung, J. Chang, M. Williams, N. Grigoryan, and et al. Peripheral administration of the selective inhibitor of soluble tumor necrosis factor (TNF) XPro(R)1595 attenuates nigral cell loss and glial activation in 6-OHDA hemiparkinsonian rats J Parkinsons Dis 4 2014 349 360
51. T. Raj, K. Rothamel, S. Mostafavi, C. Ye, M.N. Lee, J.M. Replogle, and et al. Polarization of the effects of autoimmune and neurodegenerative risk alleles in leukocytes Science 344 2014 519 523
52. J.M. Replogle, G. Chan, C.C. White, T. Raj, P.A. Winn, D.A. Evans, and et al. A TREM1 variant alters the accumulation of Alzheimer-related amyloid pathology Ann Neurol 77 2015 469 477
53. D.C. Lee, J. Rizer, J.B. Hunt, M.L. Selenica, M.N. Gordon, and D. Morgan Review: experimental manipulations of microglia in mouse models of Alzheimer's pathology: activation reduces amyloid but hastens tau pathology Neuropathol Appl Neurobiol 39 2013 69 85
54. S. Lee, N.H. Varvel, M.E. Konerth, G. Xu, A.E. Cardona, R.M. Ransohoff, and et al. CX3CR1 deficiency alters microglial activation and reduces beta-amyloid deposition in two Alzheimer's disease mouse models Am J Pathol 177 2010 2549 2562
55. J. El Khoury, M. Toft, S.E. Hickman, T.K. Means, K. Terada, C. Geula, and et al. Ccr2 deficiency impairs microglial accumulation and accelerates progression of Alzheimer-like disease Nat Med 13 2007 432 438
56. S. Ghosh, M.D. Wu, S.S. Shaftel, S. Kyrkanides, F.M. LaFerla, J.A. Olschowka, and et al. Sustained interleukin-1β overexpression exacerbates tau pathology despite reduced amyloid burden in an Alzheimer's mouse model J Neurosci 33 2013 5053 5064
57. N. Maphis, G. Xu, O.N. Kokiko-Cochran, S. Jiang, A. Cardona, R.M. Ransohoff, and et al. Reactive microglia drive tau pathology and contribute to the spreading of pathological tau in the brain Brain 138 2015 1738 1755
58. S. Lee, G. Xu, T.R. Jay, S. Bhatta, K.W. Kim, S. Jung, and et al. Opposing effects of membrane-anchored CX3CL1 on amyloid and tau pathologies via the p38 MAPK pathway J Neurosci 34 2014 12538 12546
59. M.J. Kan, J.E. Lee, J.G. Wilson, A.L. Everhart, C.M. Brown, A.N. Hoofnagle, and et al. Arginine deprivation and immune suppression in a mouse model of Alzheimer's disease J Neurosci 35 2015 5969 5982
60. E.E. Spangenberg, R.J. Lee, A.R. Najafi, R.A. Rice, M.R. Elmore, M. Blurton-Jones, and et al. Eliminating microglia in Alzheimer's mice prevents neuronal loss without modulating amyloid-β pathology Brain 139 2016 1265 1281
61. K.R. Doty, M.V. Guilllot-Sestier, and T. Town The role of the immune system in neurodegenerative disorders: adaptive or maladaptive? Brain Res 1617 2015 155 173
62. M.V. Guillot-Sestier, K.R. Doty, and T. Town Innate immunity fights Alzheimer's disease Trends Neurosci 38 2015 674 681
63. M.V. Guillot-Sestier, K.R. Doty, D. Gate, J. Rodriguez, B.P. Leung, K. Rezai-Zadeh, and et al. IL10 deficiency re-balances innate immunity to mitigate Alzheimer-like pathology Neuron 85 2015 534 548
64. P. Chakrabarty, A. Li, C. Ceballos-Diaz, J.A. Eddy, C.C. Funk, B. Moore, and et al. IL-10 alters immunoproteostasis in APP mice, increasing plaque burden and worsening cognitive behavior Neuron 85 2015 519 533
65. T. Town, Y. Laouar, C. Pittenger, T. Mori, C.A. Szekely, J. Tan, and et al. Blocking TGF-β-Smad2/3 innate immune signaling mitigates Alzheimer-like pathology Nat Med 14 2008 681 687
66. R.M. McManus, K.H. Mills, and M.A. Lynch T Cells - protective or pathogenic in Alzheimer's disease? J Neuroimmune Pharmacol 10 2015 547 560
67. M.C. Rodrigues, P.R. Sanberg, L.E. Cruz, and S. Garbuzova-Davis The innate and adative immunological aspects in neurodegenerative diseases J Neuroimmunol 269 2014 1 8
68. M. Schwartz, and K. Baruch Breaking peripheral immune tolerance to CNS antigens in neurodegenerative diseases: boosting autoimmunity to fight-off chronic neuroinflammation J Autoimmun 54 2014 8 14
69. C. Holmes Review: Systemic inflammation and Alzheimer's disease Neuropathol Appl Neurobiol 39 2013 51 68
70. E.J. Benner, R.L. Mosley, C.J. Destache, T.B. Lewis, V. Jackson-Lewis, S. Gorantla, and et al. Therapeutic immunization protects dopaminergic neurons in a mouse model of Parkinson's disease Proc Natl Acad Sci U S A 101 2004 9435 9440
71. J. Ross, S. Sharma, J. Winston, M. Nunez, G. Bottini, M. Franceschi, and et al. CHF5074 reduces biomarkers of neuroinflammation in patients with mild cognitive impairment: a 12-week, double-blind, placebo-controlled study Curr Alzheimer Res 10 2013 742 753
72. M.B. Sporn, A.B. Roberts, D.S. Goodman, and L.J. Gudas The Retinoids: Biology, Chemistry, and Medicine 2nd ed. 1994 Raven Press New York
73. K. Kawahara, M. Suenobu, H. Ohtsuka, A. Kuniyasu, Y. Sugimoto, M. Nakagomi, and et al. Cooperative therapeutic action of retinoic acid receptor and retinoid x receptor agonists in a mouse model of Alzheimer's disease J Alzheimers Dis 42 2014 587 605
74. Q. Jiang, C.Y. Lee, S. Mandrekar, B. Wilkinson, P. Cramer, N. Zelcer, and et al. ApoE promotes the proteolytic degradation of Abeta Neuron 58 2008 681 693
75. G.E. Landreth, P.E. Cramer, M.M. Lakner, J.R. Cirrito, D.W. Wesson, K.R. Brunden, and et al. Response to comments on "ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models" Science 340 2013 924-g
76. C. Balducci, A. Paladini, E. Micotti, D. Tolomeo, P. La Vitola, E. Grigoli, and et al. The Continuing Failure of Bexarotene in Alzheimer's Disease Mice J Alzheimers Dis 46 2015 471 482
77. J. Butchart, L. Brook, V. Hopkins, J. Teeling, U. Puntener, D. Culliford, and et al. Etanercept in Alzheimer disease: A randomized, placebo-controlled, double-blind, phase 2 trial Neurology 84 2015 2161 2168
78. D.S. Albrecht, C. Granziera, J.M. Hooker, and M.L. Loggia In vivo imaging of human neuroinflammation ACS Chem Neurosci 7 2016 470 483
79. G.Z. Reus, G.R. Fries, L. Stertz, M. Badawy, I.C. Passos, T. Barichello, and et al. The role of inflammation and microglial activation in the pathophysiology of psychiatric disorders Neuroscience 300 2015 141 154